7 results about "ATOPICLAIR" patented technology

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).

The present invention relates to a dermatological or dermatocosmetic composition in the form of a paraffin-free emulsion, which is particularly suitable for the treatment of inflammatory skin diseases, in particular sensitive or atopic skin. The composition comprises an aqueous phase comprising at least one emollient selected from polyols and an oily phase comprising an oily emollient system comprising at least 70% by weight of safflower oil and a second oily emollient.

The present invention relates to a dermatological or cosmetic skin composition in the form of a paraffin-free emulsion, particularly suitable for the treatment of inflammatory skin diseases, especially sensitive or atopic skin. The composition comprises an aqueous phase containing at least one emollient selected from polyols, and an oil phase containing an oily emollient system comprising at least 70% by weight of safflower oil and a second oily emollient.

A cosmetic composition for alleviating skin itching and improving atopic symptoms, according to the present invention, comprises a eutectic mixture of glutamine and linoleic acid, and exhibits the following effects: increasing the skin penetration of glutamine and enhancing skin barrier function, thereby substantially alleviating atopic symptoms including itching; improving the water solubility of linoleic acid, thereby enhancing antioxidant activity and skin protection effects; providing synergistically enhanced effects on alleviating atopic symptoms including itching and enhancing skin protection, as compared to the use of glutamine or linoleic acid alone, without adverse effects; and achieving enhanced effects in alleviating atopic symptoms including itching and improving skin protection, without adverse effects associated with surfactants and oils.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.